CN108136011A - Ezh2抑制剂和调节性t细胞功能的调制 - Google Patents

Ezh2抑制剂和调节性t细胞功能的调制 Download PDF

Info

Publication number
CN108136011A
CN108136011A CN201680057570.1A CN201680057570A CN108136011A CN 108136011 A CN108136011 A CN 108136011A CN 201680057570 A CN201680057570 A CN 201680057570A CN 108136011 A CN108136011 A CN 108136011A
Authority
CN
China
Prior art keywords
cancer
frequency
cells
cell
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680057570.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·戈施
J·M·洛拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Constellation Pharmaceuticals Inc
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CN108136011A publication Critical patent/CN108136011A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680057570.1A 2015-08-03 2016-07-28 Ezh2抑制剂和调节性t细胞功能的调制 Pending CN108136011A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200244P 2015-08-03 2015-08-03
US62/200,244 2015-08-03
PCT/US2016/044409 WO2017023671A1 (en) 2015-08-03 2016-07-28 Ezh2 inhibitors and modulation of regulatory t-cell function

Publications (1)

Publication Number Publication Date
CN108136011A true CN108136011A (zh) 2018-06-08

Family

ID=56611618

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680057570.1A Pending CN108136011A (zh) 2015-08-03 2016-07-28 Ezh2抑制剂和调节性t细胞功能的调制

Country Status (8)

Country Link
US (1) US20180221362A1 (enExample)
EP (1) EP3331561A1 (enExample)
JP (1) JP2018522045A (enExample)
CN (1) CN108136011A (enExample)
AU (1) AU2016302747A1 (enExample)
CA (1) CA2994394A1 (enExample)
HK (1) HK1256604A1 (enExample)
WO (1) WO2017023671A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020063863A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN113286601A (zh) * 2018-11-14 2021-08-20 Ionis制药公司 Foxp3表达的调节剂
CN114040776A (zh) * 2019-06-28 2022-02-11 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
CN114423426A (zh) * 2019-07-24 2022-04-29 星座制药公司 用于治疗癌症的ezh2抑制联合疗法
WO2023108563A1 (zh) * 2021-12-16 2023-06-22 北京大学第三医院（北京大学第三临床医学院） 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025933A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
JP2020522687A (ja) * 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN112007162B (zh) * 2019-05-30 2023-05-12 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
WO2024106878A1 (ko) * 2022-11-17 2024-05-23 인제대학교 산학협력단 Ezh2 저해제 및 항-pd-1 항체를 포함하는, 암의 예방 또는 치료용 약제학적 조성물
WO2025085536A1 (en) * 2023-10-16 2025-04-24 Lankenau Institute For Medical Research Biologic conjugates that inhibit production of inflammatory cells and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
CN103261890A (zh) * 2010-09-10 2013-08-21 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
CN103690531A (zh) * 2012-09-27 2014-04-02 烟台大学 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
WO2014124418A1 (en) * 2013-02-11 2014-08-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN104039956A (zh) * 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600758A (en) * 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
CN103261890A (zh) * 2010-09-10 2013-08-21 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
CN104039956A (zh) * 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗方法
CN103690531A (zh) * 2012-09-27 2014-04-02 烟台大学 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
WO2014124418A1 (en) * 2013-02-11 2014-08-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WILLIAM D.BRADLEY 等: "EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation", 《CHEMISTRY & BIOLOGY》 *
凌烈锋 等: "脱乙酰化酶抑制剂与去甲基化制剂联合作用对K562的细胞凋亡及EZH2基因表达的影响", 《皖南医学院学报》 *
郑卫东 等: "《实用流式细胞分析技术》", 31 October 2013, 广东科技出版社 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020063863A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN112512580A (zh) * 2018-09-29 2021-03-16 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN112512580B (zh) * 2018-09-29 2024-04-16 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN113286601A (zh) * 2018-11-14 2021-08-20 Ionis制药公司 Foxp3表达的调节剂
CN114040776A (zh) * 2019-06-28 2022-02-11 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
CN114040776B (zh) * 2019-06-28 2024-05-14 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
CN114423426A (zh) * 2019-07-24 2022-04-29 星座制药公司 用于治疗癌症的ezh2抑制联合疗法
CN114423426B (zh) * 2019-07-24 2024-04-05 星座制药公司 用于治疗癌症的ezh2抑制联合疗法
WO2023108563A1 (zh) * 2021-12-16 2023-06-22 北京大学第三医院（北京大学第三临床医学院） 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途

Also Published As

Publication number Publication date
HK1256604A1 (zh) 2019-09-27
AU2016302747A1 (en) 2018-02-22
US20180221362A1 (en) 2018-08-09
CA2994394A1 (en) 2017-02-09
WO2017023671A1 (en) 2017-02-09
JP2018522045A (ja) 2018-08-09
EP3331561A1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
CN108136011A (zh) Ezh2抑制剂和调节性t细胞功能的调制
Fan et al. A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy
JP6987945B2 (ja) ヒトメソテリンキメラ抗原受容体およびその使用
US20230348555A1 (en) Soluble cd33 for treating myelodysplastic syndromes (mds)
JP2022136162A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
AU2015287969B2 (en) Methods of treating cancer
Pessina et al. The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma
CN111166867B (zh) Pd-1泛素化激动剂的功能与用途
WO2022265864A9 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
KR102352127B1 (ko) Mitf 억제제를 유효성분으로 함유하는 골수-유래 억제세포 저해용 조성물
WO2018049187A1 (en) Compositions and methods of treating cancer
US20250144107A1 (en) Use of a pikfyve inhibitor in combination with immunotherapy
Kanikarla Marie et al. Preeti Kanikarla Marie1†, Alexey V. Sorokin1†, Lea A. Bitner1, Rebecca Aden1, Michael Lam1, Ganiraju Manyam2, Melanie N. Woods1, Amanda Anderson1, Anna Capasso3, Natalie Fowlkes 4, Michael J. Overman1, David G. Menter1 and Scott Kopetz1
Zhang et al. METTL5 Blockade Enhances Anti-Tumor Immune Response via Inducing Neoantigen Generation
WO2024256635A1 (en) Dpm1 inhibitor for treating cancer
Stiff Enhancing Immune Therapy for Cancer by Targeting Myeloid Derived Suppressor Cells
Su Tumor Neoantigens and a Novel Hapten Vaccine Promote Immune Targeting of Wild-Type Tumor Lineage Antigens and Improve Response to Immune Checkpoint Blockade
Yang Characterization of Inflammation and Macrophages for Novel Therapeutics and Biomarker Discovery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180608

WD01 Invention patent application deemed withdrawn after publication